Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
Palvella Therapeutics (NASDAQ: PVLA) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Jones Trading. They set a "buy" rating and a $45.00 price target on the stock.